934816-44-1

Upstream product

• 6811-77-4 3-deazaadenine 
• 2770-01-6 4-chloro-1H-imidazo[4,5-c]pyridine 
• 934816-42-9 4-(N₆,N₆-di-tert-butyloxycarbonylamino)-1-tert-butyloxycarbonyl-imidazo[4,5-c]pyridine 

Downstream Products

• 1207561-79-2 C₄₄H₄₈N₄O₇ 
• 1207561-02-1 1-[(1R,4R,5S)-3-(trityloxymethyl)-4,5-O-iso-propylidinene-2-cyclopenten-1-yl]-4-(N₆,N₆-di-tert-butyloxycarbonylamino)-imidazo[4,5-c]pyridine 
• 1374851-86-1 1-((1R,2S,3R,4R)-3-(tert-butyldiphenylsilyloxy)-4-((tert-butyldiphenylsilyloxy)methyl)-2-fluorocyclopentyl)-4-(N,N-di(tert-butyloxycarbonyl)amino)-1H-imidazo[4,5-c]pyridine 
• 1374851-88-3 1-((1R,2R,3R,4R)-3-(tert-butyldiphenylsilyloxy)-4-((tert-butyldiphenylsilyloxy)methyl)-2-fluorocyclopentyl)-4-(N,N-di(tert-butyloxycarbonyl)amino)-1H-imidazo[4,5-c]pyridine 
• 112318-10-2 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine 
• 1523571-14-3 tert-butyl (tert-butoxycarbonyl)(7-chloro-1H-imidazo[4,5-c]pyridin-4-yl)carbamate 
• 1392424-80-4 C₄₄H₄₇BrN₄O₇ 
• 1392424-79-1 C₁₆H₂₁BrN₄O₄ 

Relevant academic research and scientific papers

MLL1 INHIBITORS AND ANTI-CANCER AGENTS

The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical composit

Synthesis, conformational study and antiviral activity of L-like neplanocin derivatives

The L-like enantiomer of 9-(trans-2′, trans-3′-dihydroxycyclopent-4′-enyl)-3-deazaadenine (DHCDA) (1), its 3-deaza-3-bromo derivative (3), and the conformational restricted methanocarba (MC) nucleoside analogues (2 and 4) were synthesized. X-ray crystal structures showed the L isomer MC analogue 4 adopts a similar North-like locked conformation as conventional D-MC nucleosides, while the DHCDA analogue 3 preferred south-like conformer. Compounds 1 and 4 showed potent antiviral activity against norovirus, while compound 2 and 3 were less potent or inactive. The conformational behavior of “sugar” puckering (north/south) and nucleobase orientation (syn /anti) may contribute to the antiviral activity differences. For compound 3, antiviral activity was also found against Ebola virus.

3-Bromo-3-deazaneplanocin and 3-bromo-3-deazaaristeromycin: Synthesis and antiviral activity

As an outgrowth of our program to explore 3-deazaadenine carbocyclic nucleosides, 3-bromo-3-deazaneplanocin (5) and 3-bromo-3-deazaaristeromycin (6) have been synthesized from a readily available cyclopentenol and cyclopentanone and either 4-amino- or 4-c

CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS

The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A' is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A" is H or OR1, with the proviso that when A' is OR , A is H; and when A is OR2 , A' is H; X is C-R3 or N; Y is C-R3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R3 is H or C1-C3 alkyl; D is H or NHR2; E is absent or H; G is O or NHR2; J is N or C-R4; K is N or C-H; R4 is H, halogen (F, Cl, Br, I), CN, -C(=O)NH2, NH2, NO2, -C=C-H (cis or trans) or -C≡C-H; Ra is H or CH3; Each R1 is independently H, an acyl group, a C1 - C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R2 is independently H, an acyl group, a C1 - C20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.